Search Result

Results for "

tumor protein p53

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MDM-2/p53 (35) ACSL Family (1) Akt (3) AMPK (1) Antibiotic (1) Apoptosis (19) Autophagy (1) Bacterial (1) Bcl-2 Family (2) c-Myc (3) Caspase (8) CDK (3) Checkpoint Kinase (Chk) (1) Deubiquitinase (2) DNA Alkylator/Crosslinker (1) DNA Methyltransferase (1) DNA/RNA Synthesis (3) Drug Derivative (1) E1/E2/E3 Enzyme (6) EGFR (2) Environmental Pollutants (1) ERK (1) Eukaryotic Initiation Factor (eIF) (2) FABP (1) FAK (1) Ferroptosis (1) FLT3 (1) GLUT (1) Glutathione Peroxidase (1) HSP (1) IAP (1) Isotope-Labeled Compounds (1) JNK (2) Ligands for Target Protein for PROTAC (1) mRNA (2) mTOR (1) Orexin Receptor (OX Receptor) (1) Parasite (1) PARP (3) PERK (1) Phosphatase (2) PI3K (1) PROTACs (5) PTEN (1) Reactive Oxygen Species (ROS) (4) Small Interfering RNA (siRNA) (1) SOD (1) STAT (1) Topoisomerase (1) VEGFR (2)
By Research Areas:	Cancer (48) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (1)
Oligonucleotides:	mRNA (2) Polymers (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: MDM-2/p53 Large Tumor Suppressor (LATS) TNF Receptor BRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-156633

Rezatapopt 3 Publications Verification PC14586	MDM-2/p53	Cancer
Rezatapopt (PC14586) is an orally active antineoplastic agent. Rezatapopt binds to a pocket created by the TP53 Y220C mutation. Rezatapopt restores p53 tumor suppressor functions by stabilization of the p53 protein structure. Rezatapopt demonstrates tumor inhibition and regression in mouse models with established human tumor xenografts harboring the TP53 Y220C mutation .

HY-152859

Brigimadlin BI 907828	E1/E2/E3 Enzyme MDM-2/p53	Cancer
Brigimadlin (BI 907828) is an orally active E3 ubiquitin-protein ligase MDM-2 inhibitor, preventing MDM-2 from negatively regulating the tumor suppressor p53. Brigimadlin can be used for antineoplastic research .

HY-170451

Seldegamadlin KT-253	PROTACs MDM-2/p53 Apoptosis	Cancer
Seldegamadlin (KT-253) is a selective *p53* stabilizer and a MDM2 PROTAC degrader (DC₅₀ = 0.4 nM). Seldegamadlin inhibits the proliferation of cancer cell RS4;11 with an IC₅₀ of 0.3 nM, arrests the cell cycle at G2/M phase, and induces apoptosis. Seldegamadlin upregulates p53 activity and overcomes the p53-MDM2 feedback loop. Seldegamadlin can be used for the study of hematologic and solid tumors, such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). (Pink: ligand for target protein MDM2 ligand 4 (HY-170452); Black: linker (HY-W001478); Blue: ligand for E3 ligase cereblon (HY-163927)) .

HY-126437

Poly-L-lysine hydrobromide (MW 30000-70000) 1 Publications Verification	Apoptosis Bcl-2 Family MDM-2/p53 VEGFR	Cardiovascular Disease Cancer
Poly-L-lysine hydrobromide (MW 30000-70000) is a water-soluble synthetic polypeptide. Poly-L-lysine hydrobromide (MW 30000-70000) downregulates Bcl-2 and upregulates Bax and *p53* proteins. Poly-L-lysine hydrobromide (MW 30000-70000) promotes Apoptosis and reduces VEGF expression. Poly-L-lysine hydrobromide (MW 30000-70000) shows anticancer activity against a variety of tumors. Poly-L-lysine hydrobromide (MW 30000-70000) can also be used as a coating material .

HY-108638

NSC 146109 hydrochloride 2 Publications Verification XI-011 hydrochloride	MDM-2/p53 Apoptosis PARP	Cancer
NSC 146109 hydrochloride (XI-011 hydrochloride) is a *p53* activator and MDMX inhibitor. NSC 146109 hydrochloride inhibits MDMX gene transcription, downregulates MDMX mRNA and protein levels, stabilizes *p53* and activates the transcriptional activity of p53. NSC 146109 hydrochloride induces cancer cell apoptosis (apoptosis) and inhibits the growth of transformed cells. NSC 146109 hydrochloride inhibits the growth of xenograft tumors. NSC 146109 hydrochloride can be used in research related to breast cancer and cervical cancer .

HY-U00447

PK11000	MDM-2/p53 DNA Alkylator/Crosslinker	Cancer
PK11000 is an alkylating agent, and stabilizes the DNA-binding domain of both WT and mutant *p53* proteins by covalent cysteine modification without compromising DNA binding. PK11000 has anti-tumor activities .

HY-B1336

Furazolidone 3 Publications Verification	Environmental Pollutants Antibiotic Bacterial Apoptosis Parasite	Infection Cancer
Furazolidone is a monoamine oxidase (MAO) inhibitor with antiproliferative, apoptosis-inducing and differentiation-promoting activities. Furazolidone may inhibit leukemia fusion protein-mediated bone marrow transformation by upregulating the stability of the tumor suppressor protein p53. Furazolidone exhibits anti-leukemic activity in acute myeloid leukemia (AML) cell lines and can be used for anti-AML research [2].

HY-16366

Briciclib ON 014185	Eukaryotic Initiation Factor (eIF) CDK c-Myc MDM-2/p53 Caspase Apoptosis	Cancer
Briciclib (ON 014185) is a eukaryotic translation initiation factor 4E (eIF4E) inhibitor. Briciclib exhibits broad-spectrum anti-cancer activity, including in mantle cell leukemia, breast cancer, gastric cancer, and esophageal cancer cells. Briciclib reduces the expression of cyclin D1 and c-Myc, and enhances the expression of *P53* and Cleaved Caspase 3 pro-apoptotic proteins. Briciclib can be used for the study of hematological system tumors and solid tumors .

HY-128841

PROTAC MDM2 Degrader-2 1 Publications Verification	PROTACs MDM-2/p53 E1/E2/E3 Enzyme	Cancer
PROTAC MDM2 Degrader-2 is an MDM2 PROTAC degrader. PROTAC MDM2 Degrader-2 can induce the self-ubiquitination and degradation of MDM2, thereby upregulating the level of *p53* protein. PROTAC MDM2 Degrader-2 has anti-tumor activity and can be used in the study of cancer . (Blue: MDM2 ligand (HY-128836); Black: linker (HY-128833))

HY-N2445

Flavokawain C 4 Publications Verification	Apoptosis Akt JNK PERK Caspase PARP MDM-2/p53 IAP Reactive Oxygen Species (ROS) SOD FABP Autophagy AMPK mTOR GLUT EGFR PI3K HSP VEGFR FAK	Cancer
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant *p53* and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer .

HY-169369

TRAP-1 XJZ-06-462	MDM-2/p53 Apoptosis	Cancer
TRAP-1 (XJZ-06-462) is a non-covalent regulated induced proximity targeting chimera (RIPTAC) with JQ-1 carboxylic acid (HY-78695) as its target protein ligand. TRAP-1 forms a ternary complex with p53 ^Y220C and BRD4, potently activates p53 transcription, and inhibits the growth and proliferation of tumor cells. TRAP-1 upregulates p21 and other p53 target genes in pancreatic cell lines carrying p53 ^Y220C, and induces cellular senescence and apoptosis. TRAP-1 can be used in cancer research involving p53 ^Y220C-carrying tumors .

HY-118723

BMH-22	DNA/RNA Synthesis	Cancer
BMH-22, a benzonaphthyridin, is a RNA polymerase I (Pol I) transcription inhibitor independent of p53 function. BMH-22 causes reorganization of nucleolar marker proteins consistent with segregation of the nucleolus. BMH-22 destabilizes RPA194 in a proteasome-dependent manner and inhibits nascent rRNA synthesis and expression of the 45S rRNA precursor. BMH-22 shows potent anticancer activity across many tumor types .

HY-146887

USP7-IN-9	Deubiquitinase Apoptosis	Cancer
USP7-IN-9 is a highly potent ubiquitin-specific protease 7 (USP7) inhibitor with an IC₅₀ value of 40.8 nM. USP7-IN-9 can induce apoptosis and arrest cell progression at G0/G1 and S phases in RS4; 11 cells. USP7-IN-9 reduces the protein levels of oncoproteins MDM2 and DNMT1 and increases the protein levels of tumor suppressors p53 and p21 .

HY-128840

PROTAC MDM2 Degrader-1	PROTACs MDM-2/p53	Cancer
PROTAC MDM2 Degrader-1 (Compound 15a) is a MDM2 PROTAC degrader. The structures of both Linker ends of PROTAC MDM2 Degrader-1 are MDM2 ligands. PROTAC MDM2 Degrader-1 can not only block the binding of p53-MDM2, but also degrade the target MDM2 protein by utilizing the function of the E3 ligase of MDM2 itself, thus exerting an anti-tumor effect. (Pink: MDM2 ligand 2 (HY-128836); Black: Linker (HY-128844); Blue: E3 ligase Ligand 15 (HY-128836))

HY-172609

SL-176	Phosphatase Apoptosis MDM-2/p53 Caspase	Metabolic Disease Cancer
SL-176 is a PPM1D (Wip1) inhibitor. SL-176 inhibits lipid droplet formation, downregulates the mRNA and protein expression of PPARγ and C/EBPα, and blocks adipocyte differentiation. SL-176 induces G2/M cell cycle arrest, apoptosis and inhibits cell proliferation in breast cancer cells overexpressing PPM1D, and activates components of the *p53* pathway. SL-176 suppresses tumor growth in a zebrafish model of neuroblastoma. SL-176 is applicable to research related to obesity, breast cancer and neuroblastoma .

HY-W340839

p53-MDM2-IN-1	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53-MDM2-IN-1 (Example 30) is an inhibitor of *p53-MDM2/X* protein interaction with an K_i value of 23.35 µM. p53-MDM2-IN-1 can be used for anti-tumor research .

HY-W340313

p53-MDM2-IN-4	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53-MDM2-IN-4 (Example 4) is an inhibitor of *p53-MDM2/X* protein interaction, with a K_i value of 3.079 μM. p53-MDM2-IN-4 can be used in anti-tumor research .

HY-100765

BI-0252	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
BI-0252 is an orally active, selective *MDM2-p53* inhibitor with an IC₅₀ of 4 nM. BI-0252 can induce tumor regressions in all animals of a mouse SJSA-1 xenograft, with concomitant induction of the tumor protein p53 (TP53) target genes and markers of apoptosis .

HY-N7325

Valerosidate	PTEN Orexin Receptor (OX Receptor)	Neurological Disease Cancer
Valerosidate is an OX2R antagonist. Valerosidate increases expression of tumor suppressor proteins *p53* and PTEN, selectively reduces colon cancer cell viability, and suppresses colon cancer cell migration. Valerosidate can be used for the research of colon cancer and insomnia .

HY-169021

JNK-1-IN-3	JNK	Cancer
JNK-1-IN-3 (Compound 9e) is an inhibitor of JNK1 that downregulates JNK1 gene expression and inhibits the protein levels of its phosphorylated form, concurrently reducing the expression of its downstream targets, c-Jun and c-Fos, in tumors while restoring *p53* activity. JNK-1-IN-3 exhibits broad-spectrum antiproliferative activity, particularly with high inhibitory activity against renal and breast cancer cell lines, demonstrating both in vivo and in vitro anticancer activity .

HY-130326

RAPTA-C Ru(η6-p-cymene)Cl2(pta)	Apoptosis Caspase	Cardiovascular Disease Cancer
RAPTA-C (Ru(η6-p-cymene)Cl2(pta)) acts as an anti-cancer and anti-angiogenic agent. RAPTA-C exhibits anti-metastatic, anti-angiogenic, and anti-tumoral activities through protein and histone-deoxyribonucleic acid alterations. RAPTA-C exhibits cell growth inhibition by triggering G(2)/M phase arrest in cancer cells. RAPTA-C also enhances the levels of p53 and triggers the mitochondrial Apoptotic pathway, resulting in cytochrome C release and caspase-9 activation. RAPTA-C reduces the growth of tumors with the inhibition of angiogenesis in a ovarian carcinoma model .

HY-W034419

STIMA-1	MDM-2/p53 Apoptosis	Cancer
STIMA-1 can stimulate mutant *p53* DNA binding in vitro and induce expression of p53 target proteins and trigger apoptosis in mutant p53-expressing human tumor cells .

HY-124070

ISA 27	MDM-2/p53	Cancer
ISA 27 is a small-molecule *MDM2-p53* protein-protein interaction inhibitor. ISA 27 inhibits MDM2-mediated p53 ubiquitination and degradation. ISA 27 is promising for research of p53-mutant solid tumors (e.g., thyroid, breast cancer) .

HY-178858

PROTAC FLT3/CHK1 Degrader-1	PROTACs FLT3 Checkpoint Kinase (Chk) STAT ERK c-Myc Akt	Cancer
PROTAC FLT3/CHK1 Degrader-1 is a PROTAC FLT3/CHK1 degrader, with DC₅₀ values of 5.88 nM (FLT3) and 4.17 nM (CHK1), respectively. PROTAC FLT3/CHK1 Degrader-1 can inhibit the phosphorylation of FLT3 downstream signaling effectors STAT5 (Tyr694), AKT (Ser473), and ERK (Tyr204), downregulate the protein level of c-Myc and maintain the expression of *p53* protein. PROTAC FLT3/CHK1 Degrader-1 induces apoptosis in MV-4-11 cells. PROTAC FLT3/CHK1 Degrader-1 shows significant anti-tumor efficacy in mice bearing MV-4-11 subcutaneous xenografts. PROTAC FLT3/CHK1 Degrader-1 can be used for the study of acute myeloid leukemia (AML). (Pink: FLT3/CHK1 ligand (HY-178869 ), Blue: CRBN Ligand (HY-W093272), Black: Linker, E3 ligase ligand-linker conjugate (HY-W998238)) .

HY-146095

p53 Activator 2	MDM-2/p53 DNA/RNA Synthesis Apoptosis	Cancer
p53 Activator 2 (compound 10ah) intercalats into DNA and results in significant DNA double-strand break.p53 Activator 2 increases the expression of *p53, p-p53, CDK4, p21 to cause cell cycle arrest at G2/M phase.p53 Activator 2 induce apoptosis* and significantly down-regulates the anti-apoptosis proteins Bcl-2, Bcl-xL and the levels of cyclin B1.p53 Activator 2 has anti-proliferation activity against MGC-803 cells, with an IC₅₀ of 1.73 µM. p53 Activator 2 displays potent anticancer efficiency against MGC-803 xenograft tumors models .

HY-176457

ZS3-046	Small Interfering RNA (siRNA) MDM-2/p53 PROTACs	Cancer
ZS3-046 is a TAF1 PROTAC degrader. ZS3-046 promotes the ubiquitination and degradation of TAF1. ZS3-046 activates *p53* and induces apoptosis in acute myeloid leukemia (AML) cells. ZS3-046 has antitumor activity in an AML tumor xenograft mouse model. (Target protein ligand (HY-176467); CRBN ligase (HY-41547); Linker (HY-176469); CRBN ligase + Linker (HY-176470)) .

HY-174301

USP7-IN-18	Deubiquitinase DNA Methyltransferase MDM-2/p53	Cancer
USP7-IN-18 is a naphthalene derivative. USP7-IN-18 is a selective USP7 inhibitor (IC₅₀ : 130.9 nM), with no or very weak inhibition of the other 8 DUBs including USP47. USP7-IN-18 specifically binds to the catalytic domain of USP7, blocking its deubiquitinase activity. USP7-IN-18 causes degradation of the oncogenic proteins MDM2 and DNMT1, and also degrades the novel target PCLAF. USP7-IN-18 activates the *p53-p21* pathway. USP7-IN-18 exerts anti-tumor effects in colon cancer animal models and reshapes the tumor immune microenvironment. USP7-IN-18 achieves both direct cytotoxic and immune-synergistic anti-tumor actions.

HY-178373

Topoisomerase I-IN-18	Topoisomerase DNA/RNA Synthesis Reactive Oxygen Species (ROS) MDM-2/p53 Caspase	Cancer
Topoisomerase I-IN-18, a derivative of Thiosemicarbazide (HY-Y0032), is a Topoisomerase I inhibitor. Topoisomerase I-IN-18 can disrupt DNA synthesis and transcription. Topoisomerase I-IN-18 inhibits tumor cell proliferation by inducing S-phase cell cycle arrest. Topoisomerase I-IN-18 can enhance mitochondria-mediated apoptosis, suppress cell migration, and increase intracellular Reactive Oxygen Species (ROS) levels. Topoisomerase I-IN-18 can increase *p53* protein expression, γH2AX phosphorylation, upregulate Bax expression, downregulate Bcl-2 expression, and activate the caspase cascade. Topoisomerase I-IN-18 can be used for the study of lung cancer .

HY-P10295

p53 (232-240)	MDM-2/p53	Cancer
p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system .

HY-131667

Hdm2 E3 ligase inhibitor 1	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Hdm2 E3 ligase inhibitor 1 (Compound 1) is a reversible inhibitor for Hdm2 (an E3 ubiquitin ligase)-mediated ubiquitination of the p53 protein with an IC₅₀ of 12.7 μM. Hdm2 E3 ligase inhibitor 1 binds Hdm2, blocks Hdm2-catalyzed ubiquitin transfer from preligated Ub-Ubc4 to p53, inhibits p53 ubiquitination, stabilizes p53 protein in tumor cell and exhibits antitumor efficacy .

HY-162432

TB114	MDM-2/p53	Cancer
MDM2-IN-27 targets MDM2 protein (K_i = 0.4 nM). MDM2-IN-27 activates the anti-tumor activity of p53 and induces apoptosis by blocking the negative regulation of p53 by MDM2 .

HY-122038

NU-8165	MDM-2/p53	Cancer
NU-8165 is an inhibitor of the MDM2-p53 protein-protein interaction with anti-tumor activity. Optimization of NU-8165 was guided by MDM2 NMR titrations, which indicated key binding interaction regions. NU-8165 activated MDM2 and p21 transcription in cell-based assays and showed modest selectivity for wild-type p53 cell lines .

HY-133754

MI-1063	MDM-2/p53 Ligands for Target Protein for PROTAC	Cancer
MI-1063 is an inhibitor for MDM-2, that blocks the MDM2-p53 interaction, and activates the tumor suppressor function of p53. MI-1063 inhibits the growth of cancer cell RS4-11 and MV4-11 with IC₅₀ of 179 nM and 93 nM. MI-1063 can be used as target protein ligand in synthesis of PROTAC degrader MD-265 (HY-169327) .

HY-16271S

Kevetrin-13C2,15N3 hydrochloride 4-Isothioureidobutyronitrile-13C2,15N3 hydrochloride; thioureidobutyronitrile-13C2,15N3 hydrochloride	Isotope-Labeled Compounds MDM-2/p53	Cancer
Kevetrin (hydrochloride)- ¹³C₂, ¹⁵N₃ is the ¹³C-labeled and ¹⁵N-labeled Kevetrin (hydrochloride). Kevetrin hydrochloride is a small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity.

HY-161254

ATPase-IN-3	Apoptosis MDM-2/p53	Inflammation/Immunology Cancer
ATPase-IN-3 (compound 6) is a ATPase inhibitor. ATPase-IN-3 has Gastroprotective effect in ethanol-induced gastric ulcers by contribution of anti-apoptotic (BCL-2) and tumor suppressor (P53) proteins .

HY-174777

Human BAK1 mRNA	mRNA	Cancer
Human BAK1 mRNA encodes the human BCL2 antagonist/killer 1 (BAK1) protein, a member of the BCL2 protein family. BAK1 localizes to mitochondria, and functions to induce apoptosis. It also interacts with the tumor suppressor P53 after exposure to cell stress.

HY-174511

Human TP53 mRNA	mRNA	Cancer
Human TP53 mRNA encodes the human tumor protein p53 (TP53) protein, a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. TP53 responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism.

HY-162148

HNPMI	EGFR	Cancer
HNPMI is an inhibitor of EGFR and has cytotoxic effects on tumor cells. HNPMI can downregulate the protein levels of osteopontin, survivin and cathepsin S, leading to apoptosis. HNPMI also regulates BCL-2/BAX and p53 in CRC cell lines to inhibit tumorigenesis .

HY-155991

RUNX-IN-2	Apoptosis	Cancer
RUNX-IN-2 (Compound Conjugate 3) covalently binds to the RUNX-binding sequences, and inhibits the binding of RUNX proteins to their target sites. RUNX-IN-2 induces the p53-dependent apoptosis and inhibits cancer cell growth. RUNX-IN-2 inhibits tumor growth in PANC-1 xenograft mice. RUNX-IN-2 has high alkylation efficiency and specificity .

HY-113853

WF-10129	Akt Apoptosis	Others
WF-10129 is a cytotoxic steroidal compound isolated from the plant Physalis. WF-10129 inhibits liver cancer cell proliferation, induces apoptosis, interferes with metabolism, and significantly reduces lactate production in vitro and in vivo. WF-10129 can also exert anti-tumor activity by regulating the expression of related genes and proteins through the *AKT-p53* pathway.

HY-155852

Lepadin H	Ferroptosis Apoptosis ACSL Family Glutathione Peroxidase Reactive Oxygen Species (ROS)	Inflammation/Immunology Cancer
Lepadin H is a ferroptosis inducer and apoptosis inducer with in vitro cytotoxicity and in vivo antitumor efficacy against cancer cells. Lepadin H reduces GPX4 and SLC7A11 levels, increases p53 and ACSL4 expression, drives lipid hydroperoxide production, elevates reactive oxygen species (ROS) levels, reduces cellular glutathione (GSH) levels, induces lipid peroxidation and G₂/M phase cell cycle arrest, and suppresses clonogenic growth and migration of cancer cells.Lepadin H can be used for the research of melanoma .

HY-169002

PP5-IN-2	Phosphatase	Cancer
PP5-IN-2 is an orally active and selective protein phosphatase 5 (PP5) inhibitor with an IC₅₀ value of 0.9 μM. PP5-IN-2 activates p53 and downregulates cyclin D1 and MGMT, which shows potency in cell cycle arrest and reverses Temozolomide (TMZ) (HY-17364) resistance in the U87 MG cell line. PP5-IN-2 effectively inhibits tumor growth in the xenograft mouse model .

HY-182744

LLQ-45	MDM-2/p53	Cancer
LLQ-45 is a covalent p53 ^Y220C mutant protein agonist with an EC₅₀ of 24.97 μM. LLQ-45 activates the anti-tumor function of p53 ^Y220C through covalent modification, restores its DNA-binding ability and enhances its thermal stability. LLQ-45 selectively inhibits the proliferation of p53 ^Y220C mutant tumor cells, suppresses cell growth and upregulates the expression of CDKN1A. LLQ-45 can be used in studies related to p53 ^Y220C mutant cancers .

HY-121901

Safrole oxide	MDM-2/p53	Cancer
Safrole oxide is a *p53* modulator that upregulates the expression of the p53 tumor suppressor protein, linking cell cycle arrest to the apoptotic process. Safrole oxide induces apoptosis in lung cancer cells without triggering necrosis. Safrole oxide can be used in lung cancer-related research .

HY-164828

Rezatapopt analog-1 PC14586 analog-1	MDM-2/p53	Cancer
Rezatapopt analog-1 (PC14586 analog-1) (1919) is a Rezatapopt (HY-156633) analog. Rezatapopt binds to a pocket created by the TP53 Y220C mutation. Rezatapopt restores p53 tumor suppressor functions by stabilization of the p53 protein structure .

HY-P11490

DPMI-ω	MDM-2/p53	Inflammation/Immunology Cancer
DPMI-ω is a dual-specificity d-peptide antagonist of oncogenic proteins MDM2 and MDMX. DPMI-ω, upon fabrication on gold nanoparticles, efficiently traverses tumor cells and kills them by reactivating the *p53* signaling pathway. DPMI-ω can disrupte the p53-MDM2/MDMX complex. DPMI-ω can inhibit B16 melanoma growth and induce cells G0/G1 phase arrest. DPMI-ω can augment the efficacy of immunotherapy by expanding CD3 ⁺/CD8 ⁺ cytotoxic T cells and suppressing CD4 ⁺/CD25 ⁺ regulatory T cells companied with anti-PD1 antibody. DPMI-ω can be used for research of melanoma .

HY-16366A

Briciclib sodium ON 014185 sodium	Eukaryotic Initiation Factor (eIF) CDK c-Myc MDM-2/p53 Caspase Apoptosis	Cancer
Briciclib (ON 014185) sodium is a eukaryotic translation initiation factor 4E (eIF4E) inhibitor. Briciclib sodium exhibits broad-spectrum anti-cancer activity, including in mantle cell leukemia, breast cancer, gastric cancer, and esophageal cancer cells. Briciclib sodium reduces the expression of cyclin D1 and c-Myc, and enhances the expression of *P53* and Cleaved Caspase 3 pro-apoptotic proteins. Briciclib sodium can be used for the study of hematological system tumors and solid tumors .

HY-180820

Dimethyl bisphenolate	Drug Derivative MDM-2/p53 CDK Reactive Oxygen Species (ROS) Apoptosis Bcl-2 Family Caspase	Cancer
Dimethyl bisphenolate (Compound DMB) is a natural neolignan derivative with orally active anti-tumor activity. Dimethyl bisphenolate can inhibit cancer cells proliferation, invasion and migration. Dimethyl bisphenolate can activate the *p53* signaling pathway, upregulate the expression of p21 protein, inhibit the activity of the CDK1-cyclin B1 complex, and cause cells to stall at the G2/M phase. Dimethyl bisphenolate can induce ROS production, upregulate pro-apoptotic proteins Noxa and Bim, downregulate anti-apoptotic protein Bcl-2, activate caspase-9 and caspase-3, and ultimately induce cell apoptosis. Dimethyl bisphenolate can be used for research of glioblastoma .

HY-183831

GPS167	MDM-2/p53 PARP Caspase Apoptosis	Cancer
GPS167 is a CLK kinase inhibitor that potently and selectively inhibits recombinant human CLK1, CLK2 and CLK4. By inhibiting CLK-mediated phosphorylation of SRSF10, GPS167 upregulates the protein-binding ability of CLK1 and CLK4 with SRSF10, downregulates oncogenic BCLAF1-L and upregulates tumor-suppressive BCLAF1-S, regulates alternative splicing of genes such as MDM2 and MDM4, stabilizes *p53* protein and induces DNA damage, ultimately triggering tumor cell apoptosis. GPS167 can block the epithelial-mesenchymal transition process of tumors, activate intracellular double-stranded RNA-mediated antiviral immune responses, and produce synergistic cytotoxicity when combined with microtubule-targeting drugs. GPS167 can be used in research related to various cancers including colorectal cancer .

Cat. No.	Product Name

HY-L249

Lactylation Compound Library

5,946 compounds

Protein lactylation, an emerging post-translational modification identified in recent years, plays a critical role in linking cellular metabolic reprogramming, epigenetic regulation, and signaling networks. Based on a systematic framework encompassing lactate metabolism, lactylation, and downstream signaling pathways, this compound library comprehensively targets multiple regulatory layers, including histone modification enzymes (such as p300 and HDACs), key glycolytic enzymes (such as PKM2, LDHA, and GAPDH), transcriptional regulators (such as STAT3, HMGB1, and p53), as well as central signaling pathway nodes including HIF-1α, NF-κB, and PI3K-AKT-mTOR. This integrated design enables a comprehensive representation of the regulatory roles of lactylation across the “metabolism–epigenetics–signaling” axis.

MCE has assembled a collection of 5,946 known bioactive compounds and potential functional molecules, making this library suitable for a wide range of applications, including high-throughput drug screening, inhibitor identification, and mechanistic studies. It can be used to systematically evaluate the functional roles of lactylation in biological processes such as tumor metabolism, immune regulation, and inflammatory responses, and to efficiently identify small-molecule candidates with regulatory potential, thereby facilitating the development of innovative therapeutics targeting the interplay between metabolism and epigenetic regulation.

Cat. No.	Product Name	Type

HY-126437

Poly-L-lysine hydrobromide (MW 30000-70000)

1 Publications Verification

Biochemical Assay Reagents

Poly-L-lysine hydrobromide (MW 30000-70000) is a water-soluble synthetic polypeptide. Poly-L-lysine hydrobromide (MW 30000-70000) downregulates Bcl-2 and upregulates Bax and p53 proteins. Poly-L-lysine hydrobromide (MW 30000-70000) promotes Apoptosis and reduces VEGF expression. Poly-L-lysine hydrobromide (MW 30000-70000) shows anticancer activity against a variety of tumors. Poly-L-lysine hydrobromide (MW 30000-70000) can also be used as a coating material .

Cat. No.	Product Name	Target	Research Area

HY-P10295

p53 (232-240)	MDM-2/p53	Cancer
p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system .

HY-P11490

DPMI-ω	MDM-2/p53	Inflammation/Immunology Cancer
DPMI-ω is a dual-specificity d-peptide antagonist of oncogenic proteins MDM2 and MDMX. DPMI-ω, upon fabrication on gold nanoparticles, efficiently traverses tumor cells and kills them by reactivating the *p53* signaling pathway. DPMI-ω can disrupte the p53-MDM2/MDMX complex. DPMI-ω can inhibit B16 melanoma growth and induce cells G0/G1 phase arrest. DPMI-ω can augment the efficacy of immunotherapy by expanding CD3 ⁺/CD8 ⁺ cytotoxic T cells and suppressing CD4 ⁺/CD25 ⁺ regulatory T cells companied with anti-PD1 antibody. DPMI-ω can be used for research of melanoma .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2445

Flavokawain C 4 Publications Verification	Structural Classification Classification of Application Fields Piperaceae Plants Chalcones Flavonoids other families Phenols Polyphenols Piper methysticum G.Forst. Disease Research Fields Source Classification Cancer	Apoptosis Akt JNK PERK Caspase PARP MDM-2/p53 IAP Reactive Oxygen Species (ROS) SOD FABP Autophagy AMPK mTOR GLUT EGFR PI3K HSP VEGFR FAK
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant *p53* and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer .

HY-N7325

Valerosidate	Structural Classification Valeriana jatamansi Jones Iridoids Terpenoids Plants Valerianaceae Source Classification	PTEN Orexin Receptor (OX Receptor)
Valerosidate is an OX2R antagonist. Valerosidate increases expression of tumor suppressor proteins *p53* and PTEN, selectively reduces colon cancer cell viability, and suppresses colon cancer cell migration. Valerosidate can be used for the research of colon cancer and insomnia .

HY-113853

WF-10129	Microorganisms Ketones, Aldehydes, Acids Source Classification	Akt Apoptosis
WF-10129 is a cytotoxic steroidal compound isolated from the plant Physalis. WF-10129 inhibits liver cancer cell proliferation, induces apoptosis, interferes with metabolism, and significantly reduces lactate production in vitro and in vivo. WF-10129 can also exert anti-tumor activity by regulating the expression of related genes and proteins through the *AKT-p53* pathway.

HY-155852

Lepadin H	Structural Classification Alkaloids Animals Marine natural products Other marine organisms Quinoline Alkaloids Source Classification	Ferroptosis Apoptosis ACSL Family Glutathione Peroxidase Reactive Oxygen Species (ROS)
Lepadin H is a ferroptosis inducer and apoptosis inducer with in vitro cytotoxicity and in vivo antitumor efficacy against cancer cells. Lepadin H reduces GPX4 and SLC7A11 levels, increases p53 and ACSL4 expression, drives lipid hydroperoxide production, elevates reactive oxygen species (ROS) levels, reduces cellular glutathione (GSH) levels, induces lipid peroxidation and G₂/M phase cell cycle arrest, and suppresses clonogenic growth and migration of cancer cells.Lepadin H can be used for the research of melanoma .

Species:	Human (2) Rhesus Macaque (1) Rat (1)
Tag:	SUMO (1) His (3) Tag Free (1)
Source:	E. coli (4)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P74657

	p53 Protein, Rhesus Macaque Cellular tumor antigen p53; Tp53; Antigen NY-CO-13	Rhesus Macaque	E. coli
	p53 protein, a tumor suppressor, induces growth arrest or apoptosis in various tumors, regulating cell division through gene control, including cyclin-dependent kinase inhibitors. It stimulates BAX and FAS antigen expression or represses Bcl-2 to induce apoptosis. p53's multifaceted role underscores its importance in orchestrating cellular responses, maintaining genomic integrity, and countering aberrant cell proliferation. p53 Protein, Rhesus Macaque is the recombinant Rhesus Macaque-derived p53 protein, expressed by E. coli , with tag free.

HY-P71703

	p53 Protein, Rat (His) Tp53; p53; Cellular tumor antigen p53; tumor suppressor p53	Rat	E. coli
	The p53 protein acts as a tumor suppressor, regulates the cell cycle and induces growth arrest or apoptosis.It activates genes that inhibit cell division and trigger apoptosis by controlling the expression of various proteins.p53 Protein, Rat (His) is the recombinant rat-derived p53 protein, expressed by E.coli , with N-6*His labeled tag.

HY-P705518

	*Cellular tumor* antigen P53/TP53 Protein, Human (His)** Cellular tumor antigen p53; p53; Tp53; Antigen NY-CO-13; Phosphoprotein p53; tumor suppressor p53	Human	E. coli

HY-P72257

	Cellular tumor antigen P53/TP53, Human (His-SUMO) 1 Publications Verification BCC7; p53; p53 tumor suppressor; Phosphoprotein p5	Human	E. coli
	The cellular tumor antigen P53/TP53 is a tumor suppressor that can induce growth arrest or apoptosis in a variety of tumor types. It regulates the cell cycle by negatively controlling genes critical for division. Cellular tumor antigen P53/TP53, Human (His-SUMO) is the recombinant human-derived Cellular tumor antigen P53/TP53, expressed by E. coli , with N-SUMO, N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (4) Rabbit (7)
Reactivity:	Human (10) mouse (1) rat (1) Rat (1) Mouse (2) human (1)
Application:	WB FC ICC/IF (1) IHC-P (6) ICC/IF (6) IF-Tissue (1) IP (3) WB (8) FC (2) ELISA (3)
Isotype:	IgG (6) IgG1 (2) IgG2a (1) IgG/Kappa (1)
Conjugation:	Non-conjugated (11)
Clonality:	Monoclonal (7) Recombinant (2)
Modification:	Unmodified (8)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86169

	p53 Antibody (YA5861) Antigen NY-CO-13; BCC7; Cellular tumor antigen p53; FLJ92943; LFS1; Mutant tumor protein 53; p53; p53 tumor suppressor; p53_HUMAN; Phosphoprotein p53; Tp53; Transformation related protein 53; TRp53; tumor antigen p55; tumor protein 53; tumor protein p53; tumor suppressor p53;	WB, IHC-P, ICC/IF, IP, ELISA	Human
	p53 Antibody (YA5861) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to p53.

HY-P86277

	TP53BP2 Antibod (YA5969) Tp53BP2; ASPP2; BBP; Apoptosis-stimulating of p53 protein 2 ; Bcl2-binding protein; Bbp; Renal carcinoma antigen NY-REN-51; tumor suppressor p53-binding protein 2; 53BP2; p53-binding protein 2; p53BP2;	WB, IHC-P, ICC/IF	Human
	TP53BP2 Antibody (YA5969) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TP53BP2.

HY-P810732

	TP53INP1 Antibody (YA9976) p53DINP1; SIP; tumor protein p53-inducible nuclear protein 1; Stress-induced protein; p53-dependent damage-inducible nuclear protein 1; p53DINP1	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	TP53INP1 Antibody (YA9976) is a Rabbit-derived and non-conjugated IgG Monoclonal antibody, targeting to TP53INP1 Antibody.

HY-P81495

	p73 Antibody (YA1240) TP73; P73; tumor protein p73; p53-like transcription factor; p53-related protein	IHC-P	Human
	p73 Antibody (YA1240) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to p73.

HY-P86435

	53BP1 Antibody (YA6127) Tp53BP1; tumor suppressor p53-binding protein 1; 53BP1; p53-binding protein 1; p53BP1	WB, ICC/IF, IP, ELISA	Human
	53BP1 Antibody (YA6127) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to 53BP1.

HY-P81495A

	p73 Antibody (YA1240)(PBS only) TP73; P73; tumor protein p73; p53-like transcription factor; p53-related protein	IHC-P	Human
	p73 Antibody (YA1240) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to p73.

HY-P85577

	DR5 Antibody (YA5269) Fas like protein; Apoptosis inducing protein TRICK2A/2B; Apoptosis inducing receptor TRAIL R2; CD 262; CD262; CD262 antigen; Cytotoxic TRAIL receptor 2; Death domain containing receptor for TRAIL/Apo 2L; Death domain containing receptor for TRAIL/Apo2L; Death receptor 5; DR 5; DR5; Fas like protein precursor; KILLER; KILLER/DR5; OTTHUMP00000123492; OTTHUMP00000123493; p53 regulated DNA damage inducible cell death receptor; killer; p53 regulated DNA damage inducible cell death receptor; killer; TNF related apoptosis inducing ligand receptor 2; TNF related apoptosis inducing ligand receptor 2; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TR10B_HUMAN; TRAIL R2; TRAIL receptor 2; TRAIL-R2; TRAILR2; TRANCER; TRICK2; TRICK2A; TRICK2B; TRICKB; tumor necrosis factor receptor like protein ZTNFR9; tumor necrosis factor receptor like protein ZTNFR9; tumor necrosis factor receptor superfamily member 10b; tumor necrosis factor receptor superfamily, member 10b; ZTNFR9.	WB, ICC/IF	Human, Mouse
	DR5 Antibody (YA5269) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to DR5.

HY-P810476

	MAD1L1 Antibody (YA9774) MAD1L1, Mitotic Arrest Deficient 1 Like 1, TXBP181, MAD1, HsMAD1, Tp53I9, PIG9, Mitotic Spindle Assembly Checkpoint protein MAD1, Mitotic Arrest Deficient 1-Like protein 1, Mitotic Checkpoint MAD1 protein Homolog, MAD1 Mitotic Arrest Deficient Like 1, Tax-Binding protein 181, MAD1-Like protein 1, MAD1 (Mitotic Arrest Deficient, Yeast, Homolog)-Like 1, Mitotic-Arrest Deficient 1, Yeast, Homolog-Like 1, MAD1 Mitotic Arrest Deficient-Like 1 (Yeast), tumor protein p53 Inducible protein 9, HMAD1, MVA7	WB FC ICC/IF	Human, mouse, rat
	MAD1L1 Antibody (YA9774) is a Rabbit-derived and non-conjugated IgG Monoclonal, Recombinant antibody, targeting to MAD1L1.

HY-P89585

	TOPORS Antibody (YA8929) LUN, Tp53BPL, TOPORS, E3 ubiquitin-protein ligase Topors, RING-type E3 ubiquitin transferase Topors, SUMO1-protein E3 ligase Topors, Topoisomerase I-binding RING finger protein, Topoisomerase I-binding arginine/serine-rich protein, tumor suppressor p53-binding protein 3, p53-binding protein 3, p53BP3	WB, ICC/IF, IF-Tissue, IHC-P, IP, ELISA	human
	TOPORS Antibody (YA8929) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to TOPORS.

HY-P86745

	p63 Antibody (YA6437) P63_HUMAN; tumor protein 63; TP63; Chronic ulcerative stomatitis protein(CUSP); Keratinocyte transcription factor KET; Transformation-related protein 63(TP63); tumor protein p73-like(p73L); p40; p51; KET; P63; P73H; P73L; TP73L; AIS; LMS; NBP; RHS; p40; p51; EEC3; OFC8; SHFM4; Tp53L; p53CP; Tp53CP; B(p51A); B(p51B); P51A; TAp63gamma; P51B; TAp63alpha; P51delta; TAp63delta; P51delNalpha; deltaNp63 alpha; P51delNbeta; deltaNp63 beta; P51delNgamma; deltaNp63gamma; p40-deltaNp63; p40-deltaNp63;	WB, FC	Human
	p63 Antibody (YA6437) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to p63.

HY-P86745A

	p63 Antibody (YA6437)(PBS only) P63_HUMAN; tumor protein 63; TP63; Chronic ulcerative stomatitis protein(CUSP); Keratinocyte transcription factor KET; Transformation-related protein 63(TP63); tumor protein p73-like(p73L); p40; p51; KET; P63; P73H; P73L; TP73L; AIS; LMS; NBP; RHS; p40; p51; EEC3; OFC8; SHFM4; Tp53L; p53CP; Tp53CP; B(p51A); B(p51B); P51A; TAp63gamma; P51B; TAp63alpha; P51delta; TAp63delta; P51delNalpha; deltaNp63 alpha; P51delNbeta; deltaNp63 beta; P51delNgamma; deltaNp63gamma; p40-deltaNp63; p40-deltaNp63;	WB, FC	Human
	p63 Antibody (YA6437) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to p63.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-126437

Poly-L-lysine hydrobromide (MW 30000-70000) 1 Publications Verification		Polymers
Poly-L-lysine hydrobromide (MW 30000-70000) is a water-soluble synthetic polypeptide. Poly-L-lysine hydrobromide (MW 30000-70000) downregulates Bcl-2 and upregulates Bax and *p53* proteins. Poly-L-lysine hydrobromide (MW 30000-70000) promotes Apoptosis and reduces VEGF expression. Poly-L-lysine hydrobromide (MW 30000-70000) shows anticancer activity against a variety of tumors. Poly-L-lysine hydrobromide (MW 30000-70000) can also be used as a coating material .

HY-174777

Human BAK1 mRNA		mRNA
Human BAK1 mRNA encodes the human BCL2 antagonist/killer 1 (BAK1) protein, a member of the BCL2 protein family. BAK1 localizes to mitochondria, and functions to induce apoptosis. It also interacts with the tumor suppressor P53 after exposure to cell stress.

HY-174511

Human TP53 mRNA		mRNA
Human TP53 mRNA encodes the human tumor protein p53 (TP53) protein, a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. TP53 responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

tumor protein p53

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products